ArticleCell stem cell2019
The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Cell stem cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 56 citations in OpenAlex.
- Review
- Metabolic pathways and chemotherapy resistance in acute myeloid leukemia (AML): Insights into Enoyl-CoA hydratase domain-containing protein 3 (Cancer pathogenesis and therapy · 2026Article
- Article
- Integrated proteogenomic and metabolomic profiling of acute myeloid leukemias to identify molecular subtypes and associated therapy targets.Nature cancer · 2026Article
- Cardiolipin preserves TNature metabolism · 2026Article
- Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1Acta pharmacologica Sinica · 2026Article
- Granulopoietic Dysregulation in a Patient-Tailored Mouse Model of Barth Syndrome.Stem cell reviews and reports · 2025Article
- Article
- Bypassing Blood-Brain Barrier and Glucose Dependency of Anti-Glioblastoma Drug Candidates Targeting Mitochondrial Respiration.Journal of cellular physiology · 2025Article
- Targeting oncogenic activation of FLT3/SREBP/FASN promotes the therapeutic effect of quizartinib involving disruption of mitochondrial phospholipids.Cell death & disease · 2025Article
- Phosphatidic acid phosphatase LPIN1 in phospholipid metabolism and stemness in hematopoiesis and AML.HemaSphere · 2025Article
- Regulating Lipid MetabolismRecent patents on anti-cancer drug discovery · 2025Article
- Metabolic dependencies of acute myeloid leukemia stem cells.International journal of hematology · 2024Review
- Review
- Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer.Cancer gene therapy · 2024Article
- ACAT1 Induces the Differentiation of Glioblastoma Cells by Rewiring Choline Metabolism.International journal of biological sciences · 2024Article
- Tafazzin deficiency causes substantial remodeling in the lipidome of a mouse model of Barth Syndrome cardiomyopathy.Frontiers in molecular medicine · 2024Article
- The critical role of cardiolipin in metazoan differentiation, development, and maturation.Developmental dynamics : an official publication of the American Association of Anatomists · 2023Review
- Mechanical characterization of isolated mitochondria under conditions of oxidative stress.Biomicrofluidics · 2022Article
- In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies.Blood advances · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
36 authors at 10 institutions in 5 countries.
Ayesh K SeneviratnePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Mingjing XuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Juan J Aristizabal HenaoLaboratory of Nutritional Lipidomics, Department of Kinesiology, University of Waterloo, Waterloo, ON, Canada.
Val A FajardoDepartment of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.
Zhenyue HaoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Veronique VoisinDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
G Wei XuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Rose HurrenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
S KimPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Neil MacLeanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Xiaoming WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Marcela GrondaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Danny JeyarajuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Yulia JitkovaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Troy KetelaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Michael MullokandovDepartment of Biological Regulation, Weizmann Institute, Rehovot, Israel.
David SharonPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Geethu ThomasPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Raphaël Chouinard-WatkinsDepartment of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
James R HawleyPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Caitlin SchaferDepartment of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Helen Loo YauPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Zaza KhuchuaDepartment of Biochemistry, Sechenov Medical University, Moscow, Russian Federation; Institute of Medical Research Ilia State University, Tbilisi, Georgia.
Ahmed AmanDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada.
Rima Al-AwarDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, ON, Canada.
Atan GrossDepartment of Biological Regulation, Weizmann Institute, Rehovot, Israel.
Steven M ClaypoolDepartment of Physiology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Richard P BazinetDepartment of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Mathieu LupienPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Steven ChanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Daniel D De CarvalhoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Gary D BaderDepartment of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
Ken D StarkLaboratory of Nutritional Lipidomics, Department of Kinesiology, University of Waterloo, Waterloo, ON, Canada.
Paul LeBlancDepartment of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.
Aaron D SchimmerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Institute of Medical Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address: aaron.schimmer@uhn.ca.
Princess Margaret Cancer Centre · CAUniversity of Toronto · CAUniversity Health Network · CABrock University · CAUniversity of Waterloo · CAWeizmann Institute of Science · ILIlia State University · GEJohns Hopkins Medicine · USOntario Institute for Cancer Research · CAUniversity of Cincinnati Medical Center · US
Funding
Cytoscape: A Modeling Platform for Biomolecular NetworksR01HG009979 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2017 to 2021
$3.5MMitochondrial phosphatidylethanolamine metabolismR01GM111548 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI CLAYPOOL, STEVEN MICHAEL · 2014 to 2021
$2.8MCardiolipin and the mitochondrial ADP/ATP carrier interactomeR01HL108882 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI CLAYPOOL, STEVEN MICHAEL · 2013 to 2017
$2.0MCIHRNHGRI NIH HHS R01 HG009979NHLBI NIH HHS R01 HL108882NIGMS NIH HHS R01 GM111548
Abstract
Tafazzin (TAZ) is a mitochondrial transacylase that remodels the mitochondrial cardiolipin into its mature form. Through a CRISPR screen, we identified TAZ as necessary for the growth and viability of acute myeloid leukemia (AML) cells. Genetic inhibition of TAZ reduced stemness and increased differentiation of AML cells both in vitro and in vivo. In contrast, knockdown of TAZ did not impair normal hematopoiesis under basal conditions. Mechanistically, inhibition of TAZ decreased levels of cardiolipin but also altered global levels of intracellular phospholipids, including phosphatidylserine, which controlled AML stemness and differentiation by modulating toll-like receptor (TLR) signaling.
Indexed as
AcyltransferasesAnimalsCell Line, TumorDoxorubicinFemaleHumansLeukemia, Myeloid, AcuteMaleMiceMice, Inbred NODMice, SCIDMice, TransgenicMitochondriaPhospholipidsSignal TransductionToll-Like ReceptorsAcyltransferasesDoxorubicinPhospholipidsTAFAZZIN protein, humanToll-Like ReceptorsTranscription Factorsacute myeloid leukemiacancer differentiationcardiolipinleukemia initiating cellmitochondriaphosphatidylserinephospholipidstafazzin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.